Prostate Cell News Volume 3.00 | Jan 6 2012

LABORATORY RESEARCH

Efficient Delivery of Sticky siRNA and Potent Gene Silencing in a Prostate Cancer Model Using a Generation 5 Triethanolamine-Core PAMAM Dendrimer
In the present study, researchers demonstrate that a triethanolamine-core PAMAM dendrimer of generation 5 is able to deliver sticky siRNAs bearing complementary An/Tn 3′-overhangs effectively to a prostate cancer model in vitro and in vivo and produce potent gene silencing of the heat shock protein 27, leading to a notable anticancer effect. [Mol Pharm] Abstract

PTEN Regulates PDGF Ligand Switch for PDGF Receptor β Signaling in Prostate Cancer
In this study, researchers examined the role of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) in the regulation of platelet-derived growth factor (PDGF) expression levels using both a prostate-specific, conditional PTEN-knockout mouse model and mouse prostate epithelial cell lines established from these mice. [Am J Pathol] Abstract

Salinomycin Inhibits Prostate Cancer Growth and Migration via Induction of Oxidative Stress
Researchers studied the growth inhibitory potential of salinomycin in a panel of prostate cells. [Br J Cancer] Abstract

Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties
In this report, researchers investigated the effects of hypoxia on human prostate cancer cell lines, PC-3 and DU145. [PLoS One] Abstract

High Mobility Group Protein AT-Hook 1 (HMGA1) Is Associated with the Development of Androgen Independence in Prostate Cancer Cells
In this study, researchers evaluate the effect of HMGA1 on developing androgen independency, which is associated with the progression of prostate cancer. [Prostate] Abstract

Cediranib Inhibits Both the Intraosseous Growth of PDGF D-Positive Prostate Cancer Cells and the Associated Bone Reaction
In the current study, scientists developed a clinically relevant in vivo intraosseous tumor model overexpressing the platelet-derived growth factor D (PDGF D) to test the efficacy of a newly characterized vascular endothelial growth factor receptor/PDGFR inhibitor, cediranib. [Prostate] Abstract

LNCaP Prostate Cancer Cells with Autocrine Interleukin-6 (IL-6) Expression Are Resistant to IL-6-Induced Neuroendocrine Differentiation Due to Increased Expression of Suppressors of Cytokine Signaling
LNCaP-S17, an LNCaP subline that secretes IL-6, and LNCaP-C3, a control subline that does not express IL-6, were analyzed for IL-6-induced neuroendocrine differentiation, activation of JAK2 and STAT3 pathways, and expression of IL-6/IL-6R signaling proteins and downstream target genes. [Prostate] Abstract

Deficiency of DNA Repair Nuclease ERCC1-XPF Promotes Prostate Cancer Progression in a Tissue Recombination Model
Researchers examined the effect of excision repair cross complementing (Ercc1) gene deletion in the development of prostate cancer in a prostate recapitulation model. [Prostate] Abstract

T Cells Localized to the Androgen-Deprived Prostate Are T_H1 and T_H17 Biased
Researchers investigated the phenotype and cytokine expression of T cells at various time points in the prostates of Lewis rats following surgical castration, and used adoptive transfer of prostate-infiltrating lymphocytes to determine whether the infiltration by T cells was mediated by effects of castration on the prostate or lymphocytes. [Prostate] Abstract

CLINICAL RESEARCH

Sixteen-Year Longitudinal Changes in Serum Prostate-Specific Antigen Levels: The Olmsted County Study
The objective of this study was to determine the distribution of longitudinal changes in serum prostate-specific antigen levels from a population-based sample of men. [Mayo Clin Proc] Abstract

Weight Change and Prostate Cancer Incidence and Mortality
Scientists investigated associations between reported weight and BMI at age 18 years and measured at study entry, height, weight change between age 18 years and study entry and prostate cancer incidence and mortality. [Int J Cancer] Abstract

Phase II Study of Long-Term Androgen Suppression with Bevacizumab and Intensity-Modulated Radiation Therapy (IMRT) in High-Risk Prostate Cancer
Researchers report a Phase II trial assessing the acute and late toxicities of IMRT, long-term androgen suppression, and bevacizumab in patients with high-risk localized prostate cancer. [Int J Radiat Oncol Biol Phys] Abstract

Phase I Trial of Tremelimumab in Combination with Short-Term Androgen Deprivation in Patients with PSA-Recurrent Prostate Cancer
Researchers hypothesized that treatment with androgen deprivation, followed by an anti-CTLA-4 antibody, could augment a tumor-specific immune response elicited by androgen deprivation. [Cancer Immunol Immunother] Abstract

Cellular-Imaging Center Gets Over $8 Million to Speed Search for Earlier Diagnostic Tests and Treatments for Cancer
A team of cancer imaging experts at Johns Hopkins has embarked on a five-year research initiative to speed development of early diagnostic tests and new treatments for breast, prostate and other common cancers. [The Johns Hopkins Hospital] Press Release

Phase III Clinical Trial Begins for Prostate Cancer Immunotherapy: Cancer Vaccine May Prevent Tumor Recurrence When Combined with Standard Radiation Treatment
Advantagene Inc. and University of Massachusetts Medical School have announced the beginning of a Phase III clinical study to test the ability of a novel immunotherapy to kill tumor cells and stimulate a patient-specific anti-tumor immune response for patients newly diagnosed with localized prostate cancer. [University of Massachusetts Medical School] Press Release

Viamet Pharmaceuticals Initiates Phase I/II Clinical Trial of Novel Prostate Cancer Therapy, VT-464
Viamet Pharmaceuticals, Inc., announced that dosing has begun in a Phase I/II clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer. [Viamet Pharmaceuticals, Inc.] Press Release

Predictive Biosciences Appoints Dr. Angelo De Marzo to Leadership Team
Predictive Biosciences has announced the appointment of Dr. Angelo M. De Marzo as Chief Medical Officer. [Predictive Biosciences] Press Release

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies Inc.)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Research Fellow – Epidemiology / Prostate Studies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.